ArticleJournal of general internal medicine2026
A Health Literacy Intervention Targeting Chronic Kidney Disease Patients and Healthcare Professionals is Cost-saving: Findings from the Netherlands.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of health anxiety trajectories in rabies exposure patients based on machine learning.BMC public health · 2026Article
- Developing a Health Literacy Intervention for Hypertriglyceridemia-Induced Acute Pancreatitis: A Timing It Right Framework.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) is a progressive disease with high societal costs. CKD progression is influenced by patients' health literacy, i.e., the patients' ability to deal with information related to their own health.
objectiveTo assess the cost-effectiveness of Grip on Your Kidneys (GoYK), a multi-component health literacy intervention for CKD patients and their healthcare professionals. DESIGN AND MAIN MEASURES: We performed a cost-utility analysis of the GoYK intervention, measuring health outcomes in terms of quality-adjusted life years (QALYs) and costs in euros, and extrapolated the results to a lifetime horizon using a Markov model. SUBJECTS: The GoYK study was a quasi-experimental study involving 147 patients with CKD and 48 healthcare professionals from Dutch general practices and nephrology clinics, followed over nine months. KEY
resultsWe found that the GoYK intervention would yield a cost-saving of €28,616 and a gain of 0.37 QALYs per CKD patient across the life course. Moreover, GoYK would avert 31 deaths and 113 new dialyses per 1,000 patients in the first 10 years. These results mainly stemmed from the intervention effect on the transition to end-stage renal disease, where reductions of as little as 1% would already mean GoYK is cost-saving. The intervention remained cost-effective in multiple sensitivity and scenario analyses.
conclusionsGoYK might be a solution to slow CKD progression and, thereby, reduce CKD costs. Given these promising findings and the novelty of our study, further research should confirm our findings before broad implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.